Press Releases

Read Regulatory and non-regulatory press releases

  • All
  • Non-Regulatory
  • Regulatory

MPI – Oncology Venture looks forward to publishing a clinical update on July 2

MPI – MPI and Oncology Venture are merging – here are answers to When, How and What

MPI – Clinical data on PARP inhibitor 2X-121 and DRP response prediction validation to be presented on the world’s largest cancer congress ASCO 2018

MPI has sold its holdings in Oncology Venture

MPI – Change in Board of directors

MPI – Resolution to implement merger

MPI: Medical Prognosis Institute and Oncology Venture Announces Abstracts on Three Pipeline Products Selected for 2018 ASCO Clinical Meeting

MPI – Publication of Merger Prospectus

MPI – NOTICE TO CONVENE EXTRAORDINARY GENERAL MEETING

MPI – Publication of merger plan related to the merger between MPI and Oncology Venture

MPI – Today, April 24, 2018, the annual general meeting 2018 in Medical Prognosis Institute A/S was held

MPI’s CEO exercises warrants – increase of share capital in the company

MPI – Oncology Venture exercises option to inlicense Dovitinib a Phase 3 Multi Tyrosine Kinase Inhibitor

MPI – Notice to convene ordinary annual general meeting

Claus Frisenberg Pedersen, CFO in Oncology Venture buys shares in Oncology Venture and MPI

MPI publishes Annual report for 2017

MPI – New earlier date for publication of the annual report

MPI – Scientific journal highlights study of the DRP tool in cisplatin treatment for patients with lung cancer

Medical Prognosis Institute publishes selected financial information for the period 1 July 2017 – 31 December 2017 due to the proposed merger between Medical Prognosis Institute and Oncology Venture

Proposed merger between Medical Prognosis Institute and Oncology Venture